Related Experiment Video
Updated: Jun 17, 2026
11:52
Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
Published on: August 4, 2016
RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting
1MitoProd, 146 rue Léo Saignat, Bordeaux 33076, France. contact@mitoprod.com
Idrugs : the Investigational Drugs Journal
|December 22, 2009
Summary
RNAi therapeutics show promise in overcoming drug resistance and treating lung diseases. Novel delivery vehicles and RNA interference (RNAi) strategies are advancing RNAi-based drug discovery.
Area of Science:
- Biotechnology
- Pharmacology
- Molecular Biology
Background:
- RNA interference (RNAi) is a powerful gene-silencing mechanism with therapeutic potential.
- Drug resistance and various diseases pose significant challenges for effective treatment.
- Targeted delivery of RNAi agents is crucial for therapeutic efficacy.
Purpose of the Study:
- To report on recent advancements in RNAi-based drug discovery presented at a Boston meeting.
- To highlight novel therapeutic strategies and delivery systems for RNAi therapeutics.
- To discuss company-specific approaches and emerging RNAi technologies.
Main Methods:
- Review of selected presentations from the RNAi for Developing Targeted Therapeutics meeting.
- Focus on targeted small interfering RNA (siRNA) and small-hairpin RNA (shRNA) for drug resistance reversal.
- Discussion of EnGeneIC drug delivery vehicles, lung disease therapeutics, and topical microbicides.
Main Results:
- Demonstrated potential of targeted siRNA/shRNA in overcoming drug resistance.
- Exploration of siRNA therapeutics for lung diseases and topical microbicides.
- Presentation of novel RNAi approaches including locked nucleic acid oligonucleotides and dicer substrate siRNA.
Conclusions:
- RNAi technology is rapidly advancing, offering new therapeutic avenues.
- Innovative delivery systems and RNAi strategies are key to successful drug development.
- Companies like Alnylam Pharmaceuticals and MDRNA are actively developing RNAi therapeutics.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57piRNA - Piwi-interacting RNAs
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...